| Previous Close | 4.27 |
| Open | 4.30 |
| Volume | 598,027 |
| Avg. Volume (3M) | 1,882,343 |
| Market Cap | 533,681,856 |
| Price / Sales | 25.39 |
| Price / Book | 2.42 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Diluted EPS (TTM) | -0.550 |
| Total Debt/Equity (MRQ) | 1.86% |
| Current Ratio (MRQ) | 22.35 |
| Operating Cash Flow (TTM) | -52.67 M |
| Levered Free Cash Flow (TTM) | -68.15 M |
| Return on Assets (TTM) | -11.05% |
| Return on Equity (TTM) | -19.70% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | I-MAB | Mixed | Bullish |
AIStockmoo Score
0.0
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.0 |
| Average | 0.00 |
|
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People’s Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 10.80% |
| % Held by Institutions | 29.64% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |